1.  国家自然科学基金，面上项目，一个新乳腺癌早发相关基因PTCH2影响乳腺癌发生的分子机制研究

2.  国家高技术研究发展计划(863计划)，单细胞精确操纵与基因组测序新方法在肿瘤防治中的应用研究

3.  国家科技重大专项（重大新药创制），国家1.1类抗肿瘤新药马来酸吡咯替尼II/III期临床研究

4.  国家自然科学基金面上项目，干细胞样循环肿瘤细胞促进三阴性乳腺癌转移的遗传特征研究

5.  北京市科委“首都临床特色应用研究”专项，卡培他滨所致手足综合征易感性标记物的前瞻性、多中心临床研究

6.  中国医学科学院医学与健康科技创新工程，协同创新团队项目，基于液体活检的乳腺癌复发耐药机制及其临床应用研究

1. Pyrotinib plus capecitabine versus lapatinibplus capecitabine for the treatment of HER2-positive metastatic breast cancer(PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet Oncology, 2021. (IF=33.8)

2. The molecular tumor burden index as a responseevaluation criterion in breast cancer, Signal Transduction and Targeted Therapy, 2021. (IF=13.5) 

3.  CDK12 inhibition enhances sensitivityof HER2t breast cancers to HER2-tyrosine kinase inhibitor via suppressingPI3K/AKT. 

European Journal of Cancer, 2021. (IF=7.3) 

4. Availability of anticancerbiosimilars in 40 countries, The Lancet Oncology, 2020. (IF=33.8)

5. Chromatin modifierMTA1 regulates mitotic transition and tumorigenesis by orchestrating mitoticmRNA processing. Nat Commun, 2020.  (IF=12.1) 

6. Molecular landscape and efficacy ofHER2-targeted therapy in patients with HER2-mutated metastatic breast cancer. Npj Breast Cancer, 2020.  (IF=6.0)

7.  Pyrotinib or LapatinibCombined With Capecitabine in HER2–Positive Metastatic Breast Cancer With PriorTaxanes, Anthracyclines, and/ or Trastuzumab: A Randomized, Phase II Study, JClin Oncol, 2019. (IF=33.0)

8. Safety, Efficacy, andBiomarker Analysis of Pyrotinib in Combination with Capecitabine inHER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial, ClinCancer Res, 2019. (IF=10.1)

9. Phase I Study and BiomarkerAnalysis of Pyrotinib Pyrotinib, a Novel Irreversible Pan-ErbB ReceptorTyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth FactorReceptor 2–Positive Metastatic Breast Cancer, J Clin Oncol, 2017. (IF=33.0)